E-Scape Bio Hits $63 Million in Financing to Develop Alzheimer’s Therapy

E-Scape Bio Hits $63 Million in Financing to Develop Alzheimer’s Therapy
E-Scape Bio, the Gladstone Institutes’ spin-off company working to develop therapies for neurodegenerative disorders such as Alzheimer’s disease, announced that it has raised a total of $63 million in Series A financing from investors. The biotech startup is developing small-molecule drugs that target apoE4, a gene thought to increase the risk of Alzheimer’s disease development. E-Scape Bio aims to develop drugs that correct the adverse effects of the apolipoprotein E4 (apoE4) gene, based on decades of Alzheimer's research done at the Gladstone Institutes by E-Scape Bio’s scientific co-founders Yadong Huang, MD, PhD, and Robert Mahley, MD, PhD, both Gladstone senior investigators. ApoE
Subscribe or to access all post and page content.

2 comments

  1. Robin Smith says:

    Thank you for your good work. We are depending on the exceptional talent, imagination, and creativity of our scientists and doctors to discover how to dodge the bullet of this dreadful disease. I am a small business owner in Houston, Texas. I have been diagnosed with Alzheimer’s and it’s scary as h—. Thank you for all you do; you are very important, valued and appreciated. Robin

Leave a Comment

Your email address will not be published. Required fields are marked *